Authors

340B's Next Era: Why Hospitals Must Pair Compliance With Measurable Quality Outcomes

The future of 340B depends on integrating quality, compliance, technology, and pharmacist-led care to improve patient outcomes and strengthen audit readiness.

Maximum Dose, Minimal Gain: Rethinking Antihypertensive Dose Titration

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

The Future of Top-Selling Biologics: Biosimilars on the Rise

Key Insights From the 2025 World Drug Safety Congress Europe

Artificial intelligence, real-world data, and patient voices reshape pharmacovigilance, helping pharmacists spot risks faster and strengthen life cycle drug safety.

Exploring the Antidepressant Potential of GLP-1 Receptor Agonists

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Race-Based Medicine in the Modern Era: Historical Practice, Current Evidence, and the Pharmacist’s Role

Recent developments reflect a broader shift toward individualized, biologically informed care.

Pembrolizumab-Induced Adrenal Insufficiency: Recognizing and Managing a Diagnostic Challenge in Adjuvant NSCLC Therapy

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

Revolutionizing Treatment with Bispecific Therapies: Navigating the Challenges Ahead

By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.

Addressing Unmet Needs in Personalized Breast Cancer Treatment and ADC Sequencing

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses unanswered questions surrounding antibody-drug conjugate sequencing, biomarker testing, and medication safety in personalized breast cancer care.

Designing for Safety: The Pharma Industry’s Role in Preventing Medication Errors

Pharmaceutical companies must consider formulation, packaging, and labeling from the start to minimize errors and protect patients.

Pharmacist-Led Quality Improvement Project to Optimize Abemaciclib Dosing Within a Community Oncology Network

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Pharmacists Leading the Treatment of Multiple Myeloma: Precision Therapy and Collaborative Oncology Care

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

Dry Mouth: Its Etiology, Symptoms, and Strategies for Management

Pharmacists with a deeper knowledge of xerostomia are ideally positioned to help educate patients with dry mouth on making informed self-care decisions for effective symptom management and improved quality of life.

What Real-World Data Show About Moving Patients From Humira to Biosimilars

Data show adalimumab biosimilars can replace brand-name treatment with minimal gaps, high persistence, and sharply lower drug costs for patients and plans.

Advancing LBCL Treatment Through MRD Monitoring and Allogeneic CAR T-Cell Therapy

A phase 2 trial investigates MRD detection and therapy advancements.

Essential Oils: A Pharmacist Guide for Alternative Pain Management

With Growing Patient Interest in Natural Remedies, Pharmacists Must Understand the Science, Safety, and Limitations of Essential Oils

How Pharmacy Students Can Master Interview Skills, According to Experts

Circulating Tumor DNA (ctDNA) Testing to Predict Response in Solid Tumors

ctDNA analysis revolutionizes cancer treatment by predicting responses, detecting resistance, and monitoring minimal residual disease in patients.

From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes

Explore the rising prevalence of diabetes in the US, its various types, and the critical role pharmacists play in patient care.

Specialty Pharmacies Can Dispense the Emotional Script to Support Patients

A human-first support model helped boost adherence and outcomes, proving emotional connection is key to specialty medication success.

FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What’s Next?

The FDA ramps up action on compounded GLP‑1 weight‑loss drugs, targeting telehealth ads as Novo Nordisk sues Hims & Hers and regulators hint at seizures.

FGFR Inhibitors for Treatment of Primary CNS Tumors

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Paradoxical Hypotension After Inadvertent Intravenous Administration of Epinephrine

Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.

Revisiting Memantine: NMDA Modulation and Its Growing Relevance in Seizure Care

Beyond memantine's approved use in Alzheimer disease, emerging evidence highlights a possible role for it in select epilepsy cases.

Inside Phoebe Putney’s Medication Management Clinic: How One Rural Health System Saved $1 Million and Cut Readmissions

Darren Evans, PharmD, discusses what pharmacy leaders at other rural or regional health systems should consider before building a similar model.

Biosimilar Adoption: The Pharmacist's Role in Formulary Decisions, Patient Counseling, and Safe Use

Biosimilars lower biologic costs and widen access.

Healing Trust in Medicine in a Fractured Post-Pandemic Landscape

The pandemic’s aftermath left lasting tensions in health care.